184 related articles for article (PubMed ID: 20556807)
1. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates.
Franey H; Brych SR; Kolvenbach CG; Rajan RS
Protein Sci; 2010 Sep; 19(9):1601-15. PubMed ID: 20556807
[TBL] [Abstract][Full Text] [Related]
2. Structural Changes and Aggregation Mechanisms for Anti-Streptavidin IgG1 at Elevated Concentration.
Barnett GV; Qi W; Amin S; Lewis EN; Razinkov VI; Kerwin BA; Liu Y; Roberts CJ
J Phys Chem B; 2015 Dec; 119(49):15150-63. PubMed ID: 26563591
[TBL] [Abstract][Full Text] [Related]
3. Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies.
Thakkar SV; Sahni N; Joshi SB; Kerwin BA; He F; Volkin DB; Middaugh CR
Protein Sci; 2013 Oct; 22(10):1295-305. PubMed ID: 23893936
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of two major aggregation pathways in an IgG2 antibody.
Van Buren N; Rehder D; Gadgil H; Matsumura M; Jacob J
J Pharm Sci; 2009 Sep; 98(9):3013-30. PubMed ID: 18680168
[TBL] [Abstract][Full Text] [Related]
6. The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions.
Hui GK; Gardener AD; Begum H; Eldrid C; Thalassinos K; Gor J; Perkins SJ
J Biol Chem; 2019 Jul; 294(28):10789-10806. PubMed ID: 31088911
[TBL] [Abstract][Full Text] [Related]
7. Engineering a human IgG2 antibody stable at low pH.
Saito S; Namisaki H; Hiraishi K; Takahashi N; Iida S
Protein Sci; 2020 May; 29(5):1186-1195. PubMed ID: 32142185
[TBL] [Abstract][Full Text] [Related]
8. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration.
Kim N; Remmele RL; Liu D; Razinkov VI; Fernandez EJ; Roberts CJ
Biophys Chem; 2013 Feb; 172():26-36. PubMed ID: 23334430
[TBL] [Abstract][Full Text] [Related]
9. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.
Arosio P; Rima S; Morbidelli M
Pharm Res; 2013 Mar; 30(3):641-54. PubMed ID: 23054090
[TBL] [Abstract][Full Text] [Related]
10. Conformation and self-association of human recombinant transforming growth factor-beta3 in aqueous solutions.
Pellaud J; Schote U; Arvinte T; Seelig J
J Biol Chem; 1999 Mar; 274(12):7699-704. PubMed ID: 10075659
[TBL] [Abstract][Full Text] [Related]
11. Intermolecular interactions and conformation of antibody dimers present in IgG1 biopharmaceuticals.
Iwura T; Fukuda J; Yamazaki K; Kanamaru S; Arisaka F
J Biochem; 2014 Jan; 155(1):63-71. PubMed ID: 24155259
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
[TBL] [Abstract][Full Text] [Related]
13. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation.
Brych SR; Gokarn YR; Hultgen H; Stevenson RJ; Rajan R; Matsumura M
J Pharm Sci; 2010 Feb; 99(2):764-81. PubMed ID: 19691118
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass.
Dillon TM; Ricci MS; Vezina C; Flynn GC; Liu YD; Rehder DS; Plant M; Henkle B; Li Y; Deechongkit S; Varnum B; Wypych J; Balland A; Bondarenko PV
J Biol Chem; 2008 Jun; 283(23):16206-15. PubMed ID: 18339626
[TBL] [Abstract][Full Text] [Related]
15. Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates.
Brummitt RK; Nesta DP; Chang L; Chase SF; Laue TM; Roberts CJ
J Pharm Sci; 2011 Jun; 100(6):2087-103. PubMed ID: 21213308
[TBL] [Abstract][Full Text] [Related]
16. Conformational implications of an inversed pH-dependent antibody aggregation.
Perico N; Purtell J; Dillon TM; Ricci MS
J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
[TBL] [Abstract][Full Text] [Related]
17. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
18. The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.
Rayner LE; Hui GK; Gor J; Heenan RK; Dalby PA; Perkins SJ
J Biol Chem; 2015 Mar; 290(13):8420-38. PubMed ID: 25659433
[TBL] [Abstract][Full Text] [Related]
19. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
Schüle S; Friess W; Bechtold-Peters K; Garidel P
Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.
Latypov RF; Hogan S; Lau H; Gadgil H; Liu D
J Biol Chem; 2012 Jan; 287(2):1381-96. PubMed ID: 22084250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
